<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957292</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-DIU-2015-85</org_study_id>
    <nct_id>NCT02957292</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Menstrual Bleeding Profile Among Jaydess® and Copper Intrauterine Device (IUD) Users. COLIBRI STUDY (Copper and Levonorgestrel IUD Barcelona Research Initiative).</brief_title>
  <acronym>COLIBRI</acronym>
  <official_title>A Randomized Controlled Trial to Compare the Menstrual Bleeding Profile Among Copper and 13,5mg Levonorgestrel-releasing IUD Users.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intrauterine device (IUD) is a long-term birth control method that has demonstrated high
      contraceptive efficacy and effectiveness due to its high compliance, adherence and
      persistence of use. The IUD has a global prevalence rate around 14% in women of reproductive
      age.

      Side effects are the main reason for IUD use discontinuation. The most common reasons for
      copper IUD discontinuation are increased menstrual bleeding, irregular bleeding and
      dysmenorrhea, whereas in the case of 52mg Levonorgestrel IUD are irregular bleeding and
      amenorrhea.

      In 2014, a new hormonal IUD containing13,5mg of Levonorgestrel was marketed in Spain. There
      are many studies comparing the two Levonorgestrel IUDs. However, there is any study comparing
      the IUD 13,5mg Levonorgestrel with classic copper IUDs.

      The hypothesis of this trial is that Levonorgestrel (13,5mg) IUD users have a menstrual
      bleeding pattern with fewer days than Copper 380 mm2 IUD users.

      This is a Phase IV, national single-center, randomized 1: 1, single-blind, comparative,
      parallel controled trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of menstrual bleeding days</measure>
    <time_frame>90 days</time_frame>
    <description>Daily recorded during 90 days treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Menstrual bleeding</measure>
    <time_frame>90 days</time_frame>
    <description>Classified using a 5-item Likert-like scale from none to heavy, a pictorial blood loss assessment chart (PBAC), and ferritin and haemoglobin blood test determinations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Levonorgestrel IUD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13,5 mg Levonorgestrel intrauterine device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Copper IUD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Copper (380mm2) intrauterine device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel (13,5 mg) intrauterine device</intervention_name>
    <arm_group_label>Levonorgestrel IUD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cooper (380mm2) intrauterine device</intervention_name>
    <arm_group_label>Copper IUD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subject.

          -  Parous or nulliparous women aged between 18 and 45 years who ask for an IUD as a
             contraceptive method.

          -  History of regular cyclic menstrual periods ranged from 21 to 35 days with
             non-excessive menstrual blood loss.

        Exclusion Criteria:

          -  Absolute contraindications to IUD use, according to the World Health Organization
             Medical Eligibility Criteria.

          -  Contraindications to use 13,5 LNG-IUD.

          -  Anemia.

          -  Use of short or long-acting preparations containing sex hormones within the 12 weeks
             before the IUD insertion.

          -  Known bleeding irregularities.

          -  Pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josep Perelló, MD</last_name>
    <phone>+34935537041</phone>
    <email>jperello@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Perelló, MD</last_name>
      <phone>+34935537041</phone>
      <email>estudiocolibri2016@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

